Clinical trials show no association between the use of cholesterol-lowering drugs and Alzheimer’s or memory loss
Good news
Related Articles
Apple reportedly readies Baltra processors for AI servers
Apple is reportedly developing its data center-grade processor, Baltra, for its AI infrastructure as part of its broader effort to strengthen its Apple Silicon portfolio.
Oncology Experts Highlight Top Takeaways From the 2025 AACR Annual Meeting
Experts from across oncology specialties shared some of the most talked-about abstracts and discussions from the 2025 AACR Annual Meeting.
Urine-based hydrogen breakthrough slashes electricity demand by 27%
New research shows hydrogen can be made from human urine, offering a cheaper, cleaner alternative to traditional fossil fuels.
Elizabeth Holmes’s Partner Has a New Blood-Testing Start-Up
Billy Evans has two children with the Theranos founder, who is in prison for fraud. He’s now trying to raise money for a testing company…
DEEP Manufacturing Introduces Six-Armed Robotic HexBot System for Ultra Large-Scale WAAM – 3DPrint.com | The Voice of 3D Printing / Additive Manufacturing
UK-based DEEP Manufacturing Limited, which specializes in precision manufacturing solutions like subsea equipment, has unveiled a new robotic AM system that could help overcome some…
I am passionate about security, and these are 10 outdated security practices people still swear by
Your company is probably NOT following the latest security protocols to protect your data.
Golf Course Living Linked To Higher Parkinson’s Risk?
Incidental exposure to pesticides can elevate the risk of Parkinson’s disease for anyone living near a golf course.
Thousands attend People’s Peace Summit in Jerusalem
‘We believe that peace is possible, and the time to act is now,’ stated the organizers.
Researchers present findings that repeated anti-VEGF injections do not cause vascular issue
A study reveals that repeated anti-VEGF injections for AMD do not alter retinal vascular metrics over time, ensuring treatment stability.
Personalized Therapy, Surgical Staging, and Expanded Screening Guidelines Drive Progress in NSCLC
Isabel Preeshagul, DO, MBS, discusses the need for a nuanced approach when selecting between targeted therapies in ALK- and EGFR-altered NSCLC.